US Patent 9,248,123: Scope and Claims Analysis for Naltrexone + Bupropion Weight-Loss in Major Depressive Disorder Patients
United States Patent 9,248,123 is directed to a patient-selection and dosing method using a fixed daily exposure of naltrexone (32 mg/day) and bupropion (360 mg/day), with claims that cover single-tablet oral regimens and sustained-release formats, plus an explicit comparative limitation tying weight loss in patients with major depressive disorder (MDD) to weight loss in overweight/obese patients without MDD.
What does US 9,248,123 claim for weight loss therapy in patients with major depressive disorder?
Core claim concept (Claim 1):
A method for providing weight loss therapy by:
- Identifying an overweight or obese patient suffering from MDD.
- Reducing weight by administering a weight loss therapy comprising:
- naltrexone (or a pharmaceutically acceptable salt) at about 32 mg/day
- bupropion (or a pharmaceutically acceptable salt) at about 360 mg/day
- Including a result-based comparative limitation: the method “provides about the same amount of weight loss” in MDD patients as in non-MDD overweight/obese patients.
Why Claim 1 is the pivot
Claim 1 is built around three claim “anchors” that narrow and strengthen enforceability:
- Population anchor: overweight/obese + MDD.
- Dose anchor: specific daily amounts for both actives.
- Performance anchor: comparative “about the same amount of weight loss” vs non-MDD population.
This combination is harder to design around than claims that cover only drug composition or only general dosing.
How broad are the dose and administration limitations in US 9,248,123?
Daily dose scope (key fixed-dose language)
Claim 1 requires “about 32 mg per day” naltrexone and “about 360 mg per day” bupropion.
Derived breadth:
- “About” creates a tolerance band around each number, but the claim is still anchored to a specific exposure level. That makes the claim more difficult to avoid by dosing lower or higher without losing the “about” coverage.
Administration frequency (claims 5–7)
- Claim 5: administered once per day
- Claim 6: administered more than once per day
- Claim 7: naltrexone administered prior to or subsequent to bupropion
These dependent claims do not restrict Claim 1 to one schedule. Instead, they expand coverage to multiple practical dosing patterns that could be used by a product formulator or clinician.
Does US 9,248,123 cover once-daily vs multiple-daily regimens, and does sequencing matter?
Sequencing is covered. Claim 7 explicitly covers administration where one active precedes the other. That blocks an easy design-around based on timing order.
Frequency is covered. With Claim 5 and Claim 6, the estate spans:
- once-daily fixed combination regimens
- divided dosing schedules that still achieve the claimed daily dose exposure
Practical implication for generic entry risk:
Any generic or follow-on seeking to avoid infringement must address:
- the MDD patient-selection element
- the claimed daily dose levels (or “about” equivalents)
- and the comparative weight-loss performance limitation
The sequencing/frequency features are not likely to be a clean carve-out.
What formulation scope is protected: single oral dosage form and sustained release?
Single dosage form (Claims 8–9, 12)
-
Claim 8: naltrexone + bupropion are in a single oral dosage form
-
Claim 9: that single oral dosage form includes excipient/diluent/carrier
-
Claim 12: that single oral dosage form is further tied to sustained release when Claim 11/13/14 logic is incorporated (see below).
Sustained-release coverage (Claims 11, 13–16)
The patent includes multiple layers of sustained-release coverage:
-
Claim 11 (dependent on Claim 10): at least one of the actives is in a sustained release formulation
-
Claim 13 (dependent on Claim 10): each of naltrexone and bupropion is in sustained release
-
Claim 14: each is sustained release and in a single oral dosage form
-
Claim 15: at least one of the actives is sustained release (dependent on Claim 1)
-
Claim 16: each of the actives is sustained release (dependent on Claim 1)
Net effect: the estate is formulation-flexible. It captures:
- sustained-release for one active
- sustained-release for both actives
- combined single-tablet implementations
What is the claimed dose-escalation schedule in US 9,248,123, and how does it affect infringement?
Escalation schedule (Claim 10)
Claim 10 specifies a titration from week to week:
-
Naltrexone escalation:
- week 1: 8 mg/day
- week 2: 16 mg/day
- week 3: 24 mg/day
- week 4 and thereafter: 32 mg/day
-
Bupropion escalation:
- week 1: 90 mg/day
- week 2: 180 mg/day
- week 3: 270 mg/day
- week 4 and thereafter: 360 mg/day
Infringement-relevant consequence
- The titration schedule is a dependent narrowing feature. If a competitor product jumps directly to maintenance doses, it may avoid Claim 10 but still be captured by Claim 1 if it administers about 32 mg/day naltrexone and about 360 mg/day bupropion to the claimed patient population.
- Conversely, if a competitor follows the exact titration but treats patients outside the MDD subgroup, they may avoid the population limitation while still using similar dosing.
How strong is the “about the same amount of weight loss” comparative performance limitation?
Claim 1 includes an outcomes comparator: the method provides “about the same amount of weight loss” in MDD patients as in non-MDD overweight/obese patients.
This is an unusual and potentially high-impact limit because:
- It is not merely “weight loss occurs,” but “weight loss is about the same amount in MDD and non-MDD populations.”
- It can function as a technical/clinical definition of the method.
From a litigation standpoint, this comparative clause can:
- increase proof burden on the patentee (requiring evidence on comparative weight loss)
- but also create a sharper infringement boundary for generics or alternate indications
It is also a design-around target. If a competitor reframes use to show that weight-loss effects differ in MDD patients, they may try to argue the “about the same” result is not met.
What claims address depression symptom reduction, and how do they expand scope beyond weight loss?
- Claim 2: further comprising reducing symptoms of depression in the patient.
- Claim 18: method further reduces symptoms of depression.
These add a dual endpoint characteristic:
- weight reduction plus improvement in depression symptoms
Scope consequence:
If a clinical use label or real-world prescribing avoids depression symptom improvement (for example, focusing on weight reduction alone in MDD patients without targeting depression symptoms), defendants may argue non-infringement of these dependent claims while still facing Claim 1 coverage.
How does Claim 17 (“consists essentially of”) change the materiality of excipients and co-therapies?
- Claim 17: “pharmaceutical weight loss therapy consists essentially of” naltrexone (or salt) and bupropion (or salt).
“Consists essentially of” is narrower than “comprising.”
It generally permits:
- components that do not materially affect the basic and novel properties of the invention
It can be used to argue that:
- addition of another active ingredient that materially changes the weight loss or depression therapeutic properties may fall outside the claim
But it still allows non-active components like excipients, carriers, and diluents.
What patents likely interact with US 9,248,123 in the US for naltrexone plus bupropion weight loss?
Given only the claim text supplied, the landscape can be mapped at the level of claim families likely to exist, not with specific patent numbers. US 9,248,123’s scope implies overlap with three common patent categories in this therapeutic area:
1) Composition and combination patents (naltrexone + bupropion)
Typical claim themes:
- oral fixed-dose combinations
- salt forms
- dosage regimens
US 9,248,123 is a method claim that is more specific than many early combination patents because it adds:
- MDD patient selection
- fixed daily doses
- comparative weight-loss equivalence
- sustained release and single dosage form
2) Formulation patents (sustained release, fixed combination)
Because Claims 11, 13–16, and 14 include sustained release, there is likely an adjacent formulation patent set covering:
- sustained-release matrix design
- release profiles
- manufacturing methods
3) Method-of-use patents by patient population and endpoints
The MDD selection and depression-symptom reduction are strongly indicative of method-of-use IP. Competitors challenging this estate typically attempt:
- carve-outs by excluding MDD from the indication
- using different dose levels not covered by “about 32/360”
- changing titration approach (to target dependent Claim 10)
- attempting to show non-equivalence for the comparative outcome clause
What generic entry and biosimilar-style risk framework applies here?
This is a small-molecule method patent, so “biosimilar risk” is not the relevant analog. The correct risk lens is generic entry and Paragraph IV strategy against method claims tied to clinical use.
In practice, a generic risk pathway would focus on:
- Whether a generic label or promotional activity induces infringement of method Claim 1.
- Whether clinical protocols and patient identification processes match the MDD population requirement.
- Whether the generic achieves “about” the claimed dose exposures.
- Whether evidence supports “about the same weight loss” in MDD vs non-MDD populations in the relevant clinical setting.
If the generic product is marketed for general weight loss without targeting MDD, enforcement may rely more on off-label or induced-infringement theories.
What are the key infringement elements in Claim 1 that a challenger would target?
-
Patient identification: overweight/obese + MDD
This is often the hardest element to circumvent if the indication or promotion targets the MDD population.
-
Dose exposure: about 32 mg/day naltrexone + about 360 mg/day bupropion
A design-around can attempt to change exposure, but “about” and clinical equivalence may keep infringement arguments alive.
-
Comparative weight-loss equivalence: “about the same amount of weight loss” in MDD vs non-MDD
This is a distinct, potentially litigable endpoint limitation.
-
Weight loss therapy purpose: reducing weight
If use is not for weight reduction, the method claim does not fit.
How does the dependent-claim stack affect practical enforceability?
The claims create a layered protection structure:
- Independent: Claim 1 (MDD + overweight/obese + about 32/360 + comparative weight-loss equivalence)
- Additional dependent scope:
- Depression symptom reduction (Claims 2, 18)
- Patient subtype wording (Claims 3, 4)
- Dosing frequency and sequence (Claims 5–7)
- Single dosage form (Claims 8–9)
- Escalation schedule (Claim 10)
- Sustained release at one or both actives, and in single dosage form (Claims 11, 13–16)
- Therapy composition limitation (Claim 17)
This stack matters because it gives multiple factual hooks:
- even if one feature is disputed (for example, sustained-release format),
- Claim 1 still anchors the estate on method + dose + population + comparative outcome.
Key claim-by-claim scope map (what each dependent claim adds)
| Claim |
Adds / narrows |
Practical coverage impact |
| 1 |
MDD population + overweight/obese + about 32 mg/day naltrexone + about 360 mg/day bupropion + “about same” weight loss vs non-MDD |
Core infringement anchor |
| 2 |
reduces depression symptoms |
Adds dual endpoint for method scope |
| 3 |
patient is overweight |
Clarifies subpopulation |
| 4 |
patient is obese |
Clarifies subpopulation |
| 5 |
once per day |
Covers regimen logistics |
| 6 |
more than once per day |
Covers divided dosing |
| 7 |
naltrexone before/after bupropion |
Blocks sequencing carve-outs |
| 8 |
single oral dosage form |
Captures combination product formats |
| 9 |
includes excipient/diluent/carrier |
Standardizes formulation coverage |
| 10 |
specific week-by-week dose escalation to 32/360 |
Design-around lever if titration differs |
| 11 |
at least one sustained release |
Captures partial SR implementations |
| 12 |
SR + single oral dosage form |
Captures SR combination tablet |
| 13 |
both sustained release |
Captures full SR implementations |
| 14 |
both SR + single oral dosage form |
Captures full SR single product |
| 15 |
at least one sustained release |
SR coverage fallback |
| 16 |
both sustained release |
SR coverage fallback |
| 17 |
consists essentially of naltrexone + bupropion |
Narrows co-therapy/active additions |
| 18 |
reduces depression symptoms |
Redundant anchor on Claim 2 |
What business decisions should R&D, licensing, and litigation teams draw from this scope?
Licensing and product strategy
- A licensing strategy that relies on avoiding infringement via formulation differences (for example, immediate-release vs sustained-release) is weak against Claim 1, which is not limited to sustained release.
- A safer carve-out strategy must address at least one of Claim 1’s hard anchors: MDD patient selection, dose exposure, or the comparative weight-loss equivalence requirement.
Litigation leverage points
- The “about the same amount of weight loss” clause can become central in expert-driven proof.
- If enforcing against induced infringement, the patentee’s best leverage typically comes from:
- labeling, prescribing information, and training materials that identify MDD patients
- dosing protocols showing near-32/360 exposure
- clinical data supporting comparable outcomes between MDD and non-MDD groups
Key Takeaways
- US 9,248,123 is a method-of-use patent anchored to MDD patient selection, specific daily dose targets (about 32 mg/day naltrexone + about 360 mg/day bupropion), and a comparative weight-loss outcome requirement.
- The claim set is formulation-flexible: it covers once- or multiple-daily regimens, sequencing variations, single oral dosage forms, and sustained-release versions of one or both actives.
- The dependent claims add enforceability breadth through depression symptom reduction, specific week-by-week titration, and a “consists essentially of” limitation on the therapy composition.
- Design-around attempts that change only formulation release profile are unlikely to neutralize risk; effective carve-outs must disrupt population (MDD), dose exposure, or the comparative efficacy clause.
FAQs
1) What is the main independent claim limitation in US 9,248,123?
Claim 1 requires treating overweight/obese patients with major depressive disorder using therapy with about 32 mg/day naltrexone and about 360 mg/day bupropion, where weight loss is about the same as in non-MDD patients.
2) Do the claims require sustained-release formulations?
No. Sustained release is addressed in dependent claims (including “at least one” and “each” active in sustained release), but Claim 1 does not require sustained release.
3) Does the patent cover single-tablet combinations only?
No. It covers single oral dosage forms in dependent claims, but Claim 1 is broader and can cover other oral administration structures so long as the method elements are satisfied.
4) Is dose escalation required for infringement?
The week-by-week titration schedule is in dependent Claim 10. Claim 1 can still be implicated if the method administers the claimed daily doses to the claimed patient population.
5) What could be an effective design-around against the “about the same weight loss” limitation?
A challenger would aim to prevent the required comparative equivalence in MDD vs non-MDD populations, for example by changing the patient population definition, dosing exposure outside the “about” range, or the clinical protocol such that outcomes do not meet the “about the same” threshold.
References
- United States Patent 9,248,123. (Patent claims excerpt provided in prompt).
